Masimo (MASI) Proxy Filing summary

Executive summary

• Masimo has agreed to be acquired by Danaher for $180.00 per share, with Masimo to operate as a standalone unit within Danaher's Diagnostics segment and maintain its brand identity.

• The acquisition aims to strengthen Danaher's offering in acute care and accelerate the global scaling of Masimo's monitoring technologies.

• The transaction is subject to shareholder approval and regulatory clearances, with materials to be filed with the SEC.

• Forward-looking statements highlight anticipated benefits, but also note risks such as regulatory approvals, competing offers, and potential impacts on personnel and business relationships.

Voting matters and shareholder proposals

• Shareholders will be asked to approve the acquisition at a forthcoming meeting, with proxy materials to be distributed in advance.

• All relevant documents, including the proxy statement, will be available on the SEC's website and company investor portals.

Board of directors and corporate governance

• Directors, executive officers, and employees of both companies may be considered participants in the proxy solicitation.

• Information on directors and executive officers, including recent changes, is available in prior proxy statements and SEC filings.